ospemifene 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antiestrogens or estrogen receptor modulators, clomifene and tamoxifen derivatives 4749 128607-22-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • osphena
  • FC-1271a
  • ospemifene
  • senshio
an estrogen agonist/antagonist with tissue selective effects, its biological actions are mediated through binding to estrogen receptors, this binding results in activation of estrogenic pathways in some tissues (agonism) and blockade of estrogenic pathways in others (antagonism)
  • Molecular weight: 378.90
  • Formula: C24H23ClO2
  • CLOGP: 5.56
  • LIPINSKI: 1
  • HAC: 2
  • HDO: 1
  • TPSA: 29.46
  • ALOGS: -5.86
  • ROTB: 8

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

None

ADMET properties:

PropertyValueReference
fu (Fraction unbound in plasma) 0 % Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K

Approvals:

DateAgencyCompanyOrphan
Nov. 20, 2014 EMA Shionogi Limited
Feb. 26, 2013 FDA SHIONOGI INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hot flush 296.40 37.17 87 1289 51072 63436574
Vaginal discharge 183.56 37.17 42 1334 9156 63478490
Labelled drug-drug interaction medication error 182.97 37.17 45 1331 13354 63474292
No adverse event 121.05 37.17 42 1334 41363 63446283
Vaginal haemorrhage 121.02 37.17 38 1338 27449 63460197
Muscle spasms 108.41 37.17 57 1319 156093 63331553
Therapeutic response unexpected 99.76 37.17 30 1346 18729 63468917
Vulvovaginal burning sensation 72.03 37.17 15 1361 2094 63485552
Vulvovaginal discomfort 64.59 37.17 14 1362 2364 63485282
Inability to afford medication 59.18 37.17 13 1363 2334 63485312
Off label use 55.40 37.17 70 1306 674392 62813254
Vulvovaginal pruritus 49.80 37.17 12 1364 3231 63484415
Hyperhidrosis 49.19 37.17 30 1346 107806 63379840
Labelled drug-disease interaction medication error 39.14 37.17 6 1370 144 63487502

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hot flush 233.23 42.21 65 938 54812 79688573
Vaginal discharge 137.78 42.21 29 974 7434 79735951
Labelled drug-drug interaction medication error 104.51 42.21 30 973 27620 79715765
Vaginal haemorrhage 97.54 42.21 27 976 21790 79721595
Muscle spasms 93.99 42.21 45 958 174685 79568700
Therapeutic response unexpected 76.91 42.21 22 981 19924 79723461
No adverse event 63.42 42.21 22 981 37170 79706215
Vulvovaginal discomfort 63.12 42.21 12 991 1826 79741559
Vulvovaginal burning sensation 52.05 42.21 10 993 1607 79741778
Off label use 45.51 42.21 56 947 907159 78836226

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC G03XC05 GENITO URINARY SYSTEM AND SEX HORMONES
SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
OTHER SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM
Selective estrogen receptor modulators
FDA MoA N0000000168 Selective Estrogen Receptor Modulators
FDA EPC N0000175826 Estrogen Agonist/Antagonist
CHEBI has role CHEBI:35610 antineoplastic agents
CHEBI has role CHEBI:67079 anti-inflammatory agents

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Dyspareunia indication 71315007
Atrophic vulva indication 248861000 DOID:14275




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
60MG OSPHENA DUCHESNAY N203505 Feb. 26, 2013 RX TABLET ORAL 8470890 Feb. 13, 2024 TREATMENT OF DYSPAREUNIA ASSOCIATED WITH MENOPAUSE
60MG OSPHENA DUCHESNAY N203505 Feb. 26, 2013 RX TABLET ORAL 8470890 Feb. 13, 2024 TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY, ASSOCIATED WITH MENOPAUSE
60MG OSPHENA DUCHESNAY N203505 Feb. 26, 2013 RX TABLET ORAL 8470890 Feb. 13, 2024 TREATMENT OF VAGINAL SYMPTOMS OF UROGENITAL ATROPHY BY ORALLY ADMINISTERING OSPEMIFENE WITH FOOD TO ENHANCE BIOAVAILABILITY OF OSPEMIFENE
60MG OSPHENA DUCHESNAY N203505 Feb. 26, 2013 RX TABLET ORAL 8772353 Feb. 13, 2024 TREATMENT OF DYSPAREUNIA ASSOCIATED WITH MENOPAUSE
60MG OSPHENA DUCHESNAY N203505 Feb. 26, 2013 RX TABLET ORAL 8772353 Feb. 13, 2024 TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY, ASSOCIATED WITH MENOPAUSE
60MG OSPHENA DUCHESNAY N203505 Feb. 26, 2013 RX TABLET ORAL 8772353 Feb. 13, 2024 TREATMENT OF VAGINAL SYMPTOMS OF UROGENITAL ATROPHY BY ORALLY ADMINISTERING OSPEMIFENE WITH FOOD TO ENHANCE BIOAVAILABILITY OF OSPEMIFENE
60MG OSPHENA DUCHESNAY N203505 Feb. 26, 2013 RX TABLET ORAL 9241915 Feb. 13, 2024 TREATMENT OF DYSPAREUNIA ASSOCIATED WITH MENOPAUSE
60MG OSPHENA DUCHESNAY N203505 Feb. 26, 2013 RX TABLET ORAL 9241915 Feb. 13, 2024 TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY, ASSOCIATED WITH MENOPAUSE
60MG OSPHENA DUCHESNAY N203505 Feb. 26, 2013 RX TABLET ORAL 9241915 Feb. 13, 2024 TREATMENT OF VAGINAL SYMPTOMS OF UROGENITAL ATROPHY BY ORALLY ADMINISTERING OSPEMIFENE WITH FOOD TO ENHANCE BIOAVAILABILITY OF OSPEMIFENE
60MG OSPHENA DUCHESNAY N203505 Feb. 26, 2013 RX TABLET ORAL 9855224 Feb. 13, 2024 TREATMENT OF DYSPAREUNIA ASSOCIATED WITH MENOPAUSE
60MG OSPHENA DUCHESNAY N203505 Feb. 26, 2013 RX TABLET ORAL 9855224 Feb. 13, 2024 TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY, ASSOCIATED WITH MENOPAUSE
60MG OSPHENA DUCHESNAY N203505 Feb. 26, 2013 RX TABLET ORAL 9855224 Feb. 13, 2024 TREATMENT OF VAGINAL SYMPTOMS OF UROGENITAL ATROPHY BY ORALLY ADMINISTERING OSPEMIFENE WITH FOOD TO ENHANCE BIOAVAILABILITY OF OSPEMIFENE
60MG OSPHENA DUCHESNAY N203505 Feb. 26, 2013 RX TABLET ORAL 6245819 July 21, 2025 TREATMENT OF DYSPAREUNIA ASSOCIATED WITH MENOPAUSE
60MG OSPHENA DUCHESNAY N203505 Feb. 26, 2013 RX TABLET ORAL 6245819 July 21, 2025 TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY, ASSOCIATED WITH MENOPAUSE
60MG OSPHENA DUCHESNAY N203505 Feb. 26, 2013 RX TABLET ORAL 8236861 Aug. 11, 2026 TREATMENT OF DYSPAREUNIA ASSOCIATED WITH MENOPAUSE
60MG OSPHENA DUCHESNAY N203505 Feb. 26, 2013 RX TABLET ORAL 8236861 Aug. 11, 2026 TREATMENT OF MODERATE TO SEVERE VAGINAL DRYNESS AND PAIN WITH INTERCOURSE, SYMPTOMS OF VULVAR AND VAGINAL ATROPHY, ASSOCIATED WITH MENOPAUSE
60MG OSPHENA DUCHESNAY N203505 Feb. 26, 2013 RX TABLET ORAL 8236861 Aug. 11, 2026 TREATMENT OF VAGINAL SYMPTOMS OF UROGENITAL ATROPHY BY ORALLY ADMINISTERING OSPEMIFENE WITH FOOD TO ENHANCE BIOAVAILABILITY OF OSPEMIFENE

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Estrogen receptor Nuclear hormone receptor MODULATOR IC50 6.08 WOMBAT-PK CHEMBL
Estrogen receptor beta Nuclear hormone receptor ANTAGONIST Ki 6.39 IUPHAR

External reference:

IDSource
D08958 KEGG_DRUG
4032347 VANDF
CHEBI:73275 CHEBI
CHEMBL2105395 ChEMBL_ID
C119141 MESH_SUPPLEMENTAL_RECORD_UI
7349 IUPHAR_LIGAND_ID
7859 INN_ID
DB04938 DRUGBANK_ID
B0P231ILBK UNII
1370971 RXNORM
199207 MMSL
29311 MMSL
d08070 MMSL
014918 NDDF
716223004 SNOMEDCT_US
C1313616 UMLSCUI
3036505 PUBCHEM_CID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Osphena HUMAN PRESCRIPTION DRUG LABEL 1 55494-580 TABLET, FILM COATED 60 mg ORAL NDA 28 sections
Osphena HUMAN PRESCRIPTION DRUG LABEL 1 59630-580 TABLET, FILM COATED 60 mg ORAL NDA 29 sections
Osphena HUMAN PRESCRIPTION DRUG LABEL 1 59630-580 TABLET, FILM COATED 60 mg ORAL NDA 29 sections
Osphena HUMAN PRESCRIPTION DRUG LABEL 1 59630-580 TABLET, FILM COATED 60 mg ORAL NDA 29 sections
Osphena HUMAN PRESCRIPTION DRUG LABEL 1 75929-178 TABLET, FILM COATED 60 mg ORAL NDA 29 sections